ABPI 150
Alternative Names: ABP 150Latest Information Update: 14 Mar 2007
Price :
$50 *
At a glance
- Originator Apollo BioPharmaceutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 07 Sep 2006 Discontinued - Phase-I for Parkinson's disease in USA (unspecified route)
- 07 Sep 2004 No development reported - Phase-I for Parkinson's disease in USA (unspecified route)
- 10 Sep 2001 Phase-I clinical trials for Parkinson's disease in USA (Unknown route)